203. 22q11.2欠失症候群 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 5 / 薬物数 : 7 - (DrugBank : 1) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 24

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Concerta
   University of Geneva, Switzerland
      2016   -   NCT04647500   Switzerland
Emea/H/C/000109
   Academisch ziekenhuis Maastricht
      2021   Phase 3   EUCTR2021-002011-61-NL   Netherlands
NFC-1
   Aevi Genomic Medicine, LLC, a Cerecor company
      2016   Phase 1   NCT02895906   United States
Rilutek
   Academisch ziekenhuis Maastricht
      2021   Phase 3   EUCTR2021-002011-61-NL   Netherlands
Riluzole
   Academisch ziekenhuis Maastricht
      2021   Phase 3   EUCTR2021-002011-61-NL   Netherlands
Risperdal
   University of Geneva, Switzerland
      2017   -   NCT04639960   Switzerland
ZYN002
   Zynerba Pharmaceuticals, Inc.
      2020   Phase 1/Phase 2   NCT05149898   Australia;United States